GLPwatch
Papers (10386)
Page 140 of 174, ranked by citation count.
- Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
- [For obese patients or for patients who are overweight and have an associated comorbidity, how safe and effective is semaglutide as compared with placebo as an adjunct to lifestyle intervention for reducing body weight and other related end points?]
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide.
- [Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].
- Sixty seconds on . . . semaglutide.
- Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions.
- Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI.
- GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.
- [Natriuretic effect of exenatide: high efficacy and site of action].
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity.
- Validation of a Questionnaire for Assessing the Emotional Impact of Treatment for Type 2 Diabetes.
- GLP-1 Receptor Agonists and Psychiatric Outcomes in Adolescents: A Systematic Review and Meta-Analysis.
- Engineering Marker-Free Lettuce Chloroplast Genome to Express Functional Glucagon-Like Peptide-1 Receptor Agonists Exenatide and Lixisenatide.
- [Effects of antidiabetic medications on metabolic-associated fatty liver disease].
- Disease-modifying effect, safety and optimal dose of oral semaglutide tablets for patients with Parkinson's disease (MOST-ABLE study): protocol for a randomised, double-blind, placebo-controlled study.
- The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.
- Pharmacokinetic-pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus.
- Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.
- Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet.
- Is pharmacotherapy enough for urgent weight loss in severely obese patients?
- A randomized controlled trial protocol of the cardiovascular safety and efficacy of liraglutide in the treatment of type 2 diabetes.
- Exenatide improves cisplatin induced ovarian damage through NLRP3, Nrf-2, and TLR4 pathways.
- Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.
- Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.
- Metformin-Enhanced Digital Therapeutics for the Affordable Primary Prevention of Diabetes and Cardiovascular Diseases: Advancing Low-Cost Solutions for Lifestyle-Related Chronic Disorders.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Semaglutide: A New Medical Swiss Army Knife?
- Semaglutide and Cardiovascular Outcomes. Reply.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Liraglutide attenuates aluminum chloride-induced Alzheimer's disease in rats by modulating the oxLDL/LPA/LPAR1 pathway.
- Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity.
- Effects of exenatide on microvascular reactivity in patients with type 2 diabetes and coronary artery disease: A randomized controlled study.
- Retatrutide.
- Liraglutide orchestrates ferroptosis defense against murine cisplatin acute kidney injury: NRF2 activation via both KEAP1-dependent and -independent mechanisms is essential for SLC7A11/GPX4 renoprotection.
- ▾ Liraglutide for weight management.
- Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
- Knowledge, attitude and practice toward liraglutide and semaglutide among endocrinology medical staff.
- Liraglutide: Weight loss injection is effective in children aged 6-11, study reports.
- Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
- ForePass outperforms Semaglutide in weight control, glucose metabolism, and gut microbiota in swine.
- Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.
- Comparison of trajectories of self-monitored glucose levels by hypoglycemia status over 52 weeks of treatment with insulin glargine or exenatide once weekly.
- Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.
- Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.
- More on Semaglutide in Early Type 1 Diabetes.
- Ethical Considerations in the Use of Weight Loss Medications.
- A Retrospective Analysis of Liraglutide (GLP-1 Agonist) Use in a Chinchilla (<i>Chinchilla lanigera</i>) Model of Auditory Blast Injury.
- Once-Weekly Mazdutide in Obesity or Overweight. Reply.
- Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
- ADDITION OF DULAGLUTIDE FOR A HIGH-DOSE INSULIN REQUIRING PATIENT WITH TYPE 2 DIABETES MELLITUS: A REMARKABLE RESPONSE.
- Design and evaluation of novel thrombin-based GLP-1 analogs with peptidic albumin binding domain for the controlled release of GLP-1.
- Influence of pH, Buffering Capacity, Ionic Strength, Bile Salts, and Model Drugs on Micellization Behaviour of Salcaprozate Sodium in Physiological Range pH Buffers.
- Translating Guidelines into Practice: A Prospective Real-World Study of a Romanian Cohort Treated with GLP-1 RAs.
- High Dose of Liraglutide Impairs Renal Function in Female Hypertensive Rats.
- Efficacy and Safety of Pharmacological, Endoscopic, and Surgical Treatments for Obesity: A GRADE-Based Network Meta-Analysis.
- Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.
- The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Alcohol Use Disorder: Current Evidence and Future Directions.
- Detection of adverse drug reactions among ordinary users of liraglutide on the occasion of drug dispensing in the community pharmacy setting.